Discovery of a Series of 6,7-Dimethoxy-4-pyrrolidylquinazoline PDE10A Inhibitors
Journal of Medicinal Chemistry2006Vol. 50(2), pp. 182–185
Citations Over TimeTop 16% of 2006 papers
Thomas A. Chappie, John M. Humphrey, Martin P. Allen, Kimberly G. Estep, Carol B. Fox, Lorraine A. Lebel, Spiros Liras, Eric S. Marr, Frank S. Menniti, Jayvardhan Pandit, Christopher J. Schmidt, Meihua Tu, Robert D. Williams, Feng V. Yang
Abstract
A papaverine based pharmacophore model for PDE10A inhibition was generated via SBDD and used to design a library of 4-amino-6,7-dimethoxyquinazolines. From this library emerged an aryl ether pyrrolidyl 6,7-dimethoxyquinazoline series that became the focal point for additional modeling, X-ray, and synthetic efforts toward increasing PDE10A inhibitory potency and selectivity versus PDE3A/B. These efforts culminated in the discovery of 29, a potent and selective brain penetrable inhibitor of PDE10A.
Related Papers
- → <i>In-Silico</i> Identification of Anticancer Compounds; Ligand-Based Pharmacophore Approach against EGFR Involved in Breast Cancer(2021)6 cited
- → Advances in Pharmacophore Modeling and Its Role in Drug Designing(2020)4 cited
- → PHARMACOPHORE BASED SCREENING OF EPICATECHIN AGAINST COLON CANCER(2012)1 cited
- → 3D Pharmacophore Modeling Techniques in Computer‐Aided Molecular Design Using LigandScout(2017)41 cited
- → Computational Modeling of Selective Pharmacophores at the α 1 ‐Adrenergic Receptors(2008)2 cited